Drugs.com - Clinical Trials

Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity

LOS ANGELES, Calif., February 11, 2025 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced topline results from...

Feb 13, 2025 - 04:24
 0
Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity
LOS ANGELES, Calif., February 11, 2025 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced topline results from...
Read More

Tags:

Previous Article

South32 downplays interest in Anglo's GEMCO share as profits surge

Next Article

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administratio...

Related Posts

Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease

Genentech’s Phase IIb Study of Prasinezumab Missed Prim...

Feb 9, 2025  0

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Pyxis Oncology Granted FDA Fast Track Designation for P...

Feb 27, 2025  0

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Innate Pharma Announces U.S. FDA Granted Breakthrough T...

Feb 17, 2025  0